Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betalutin Dosimetry and PK in Relapsed Non-Hodgkin Lymphoma
NCT02657447Phase 1Withdrawn
- Sponsor
- Nordic Nanovector ASA
- Start
- Dec 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lutetium (177Lu) lilotomab satetraxetan in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Nordic Nanovector ASA. Primary endpoint: Radiation Dosimetry at 3 weeks. Planned start Dec 2017; status: withdrawn.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02657447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657447.